Weight-loss drugs are transforming health care and Wall Street, but exciting prospects don’t necessarily mean a company is a good investment.

Robert F. Kennedy Jr., President Trump's nominee to lead HHS, spoke highly of GLP-1 drugs at a Senate confirmation hearing ...

An analyst thinks he has cracked the code on why highflying Eli Lilly missed two quarters of Wall Street projections.

Anti-obesity drug Mounjaro is set to rack up global sales worth nearly £22bn a year by the end of the decade. But Donald ...

Novo Nordisk announced positive trial results for its next-generation obesity drug, leading to a 7.13% surge in its share ...

Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

Novo Nordisk (NVO) stock jumped 12% in pre-market trading Friday after it released promising results of an early-stage weight ...

One of Novo Nordisk's next-generation obesity shots to follow up on the success of Wegovy helped patients lose 22% of their ...

Shares of pharmaceutical giant Eli Lilly (NYSE:LLY) edged down 1.2% in premarket trading following announcements from ...